Emavusertib (mesylate)

• Description:

  Emavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib (HY-135317) . Emavusertib mesylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib mesylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib mesylate exhibits antitumor activity in mouse model[1][2][3].

• Product Name Alternative:

  CA-4948 (mesylate)

• UNSPSC:

  12352005

• Target:

  Apoptosis; FLT3; IRAK; MyD88; NF-κB

• Related Pathways:

  Apoptosis; Immunology/Inflammation; NF-κB; Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer; Inflammation/Immunology

• Smiles:

  CS (=O) (O) =O.O=C (C1=COC (C2=CC=NC (C) =C2) =N1) NC3=C (N4CC[C@H] (C4) O) N=C5C (OC (N6CCOCC6) =N5) =C3

• Molecular Formula:

  C25H29N7O8S

• Molecular Weight:

  587.60

• References & Citations:

  [1]Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.|[2]Guidetti F, et al. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. J Clin Med. 2023 Jan 4;12 (2) :399. |[3]Parrondo RD, et al. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023 Oct 26;14:1239082.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  2376399-40-3